Cargando…

Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A systematic review and meta-analysis

OBJECTIVES: Androgen deprivation therapy combined with radiotherapy for intermediate-risk prostate cancer is still a matter of debate. We conducted a meta-analysis to evaluate the necessity of androgen deprivation therapy combined with radiotherapy for intermediate-risk prostate cancer patients. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jiuzhou, Yuan, Yan, Fang, Miao, Zhu, Youqi, Sun, Xueqing, Lou, Yufei, Xin, Yong, Zhou, Fengjuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887024/ https://www.ncbi.nlm.nih.gov/pubmed/36733800 http://dx.doi.org/10.3389/fendo.2022.1074540

Ejemplares similares

Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for locally advanced gastric cancer: a systematic review and meta-analysis
por: Zhu, Youqi, et al.
Publicado: (2023)

Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
por: Amit, Uri, et al.
Publicado: (2019)

Immunosuppressive environment in response to androgen deprivation treatment in prostate cancer
por: Qin, Caipeng, et al.
Publicado: (2022)

Assessment of oligometastasis status of prostate cancer following combined robot-assisted radical prostatectomy and androgen deprivation versus androgen deprivation therapy alone using PSA percentage decline rate
por: Li, Xuwen, et al.
Publicado: (2023)

Patients’ Preferences for Androgen Deprivation Therapy in the Treatment of Intermediate-Risk Prostate Cancer
por: De, Brian, et al.
Publicado: (2022)

Is neoadjuvant androgen deprivation therapy beneficial in prostate cancer treated with definitive radiotherapy?
por: Eom, Keun-Yong, et al.
Publicado: (2014)

Cardiometabolic Complications after Androgen Deprivation Therapy in a Man with Prostate Cancer: Effects of 3 Years Intermittent Testosterone Supplementation
por: Aversa, Antonio, et al.
Publicado: (2012)

Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy
por: Bracci, Stefano, et al.
Publicado: (2016)

Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
por: Røe, Kathrine, et al.
Publicado: (2012)

Neoadjuvant chemoradiotherapy for resectable gastric cancer: A meta-analysis
por: Chen, Jiuzhou, et al.
Publicado: (2022)

Intermediate-risk prostate cancer patients treated with androgen deprivation therapy and a hypofractionated radiation regimen with or without image guided radiotherapy
por: Valeriani, Maurizio, et al.
Publicado: (2013)

Impact of Androgen Deprivation Therapy Associated to Conformal Radiotherapy in the Treatment of D’Amico Intermediate-/High-Risk Prostate Cancer in Older Patients
por: Couderc, Anne-Laure, et al.
Publicado: (2020)

Infiltrating immune cells in prostate cancer tissue after androgen deprivation and radiotherapy
por: Erlandsson, Ann, et al.
Publicado: (2023)

Oncologic Outcomes of Radical Prostatectomy and High-Dose Intensity-Modulated Radiotherapy with Androgen-Deprivation Therapy for Relatively Young Patients with Unfavorable Intermediate-Risk Prostate Adenocarcinoma
por: Wu, Szu-Yuan, et al.
Publicado: (2021)

Radiotherapy Combined With Androgen Deprivation for Bone Oligometastases After Primary Curative Radiotherapy for Prostate Cancer: A Retrospective Study
por: Wu, Jun-Xin, et al.
Publicado: (2016)

A novel BRCA2 mutation in prostate cancer sensitive to combined radiotherapy and androgen deprivation therapy
por: Liu, Qiuli, et al.
Publicado: (2018)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Trends in Androgen Deprivation Use in Men With Intermediate-Risk Prostate Cancer Who Underwent Radiation Therapy
por: Agrawal, Vishesh, et al.
Publicado: (2022)

Non-Genomic Actions of the Androgen Receptor in Prostate Cancer
por: Leung, Jacky K., et al.
Publicado: (2017)

Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis
por: Chen, Xiangyu, et al.
Publicado: (2023)

Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer
por: Mason, Malcolm D., et al.
Publicado: (2015)

Prostate-specific antigen dynamics after neoadjuvant androgen-deprivation therapy and carbon ion radiotherapy for prostate cancer
por: Takakusagi, Yosuke, et al.
Publicado: (2020)

Radiotherapy plus androgen deprivation therapy for prostate‐specific antigen persistence in lymph node–positive prostate cancer
por: Shiota, Masaki, et al.
Publicado: (2022)

Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma
por: Sanguineti, G, et al.
Publicado: (2002)

Benefit of Whole Pelvic Radiotherapy Combined with Neoadjuvant Androgen Deprivation for the High-Risk Prostate Cancer
por: Milecki, Piotr, et al.
Publicado: (2009)

Multimodal therapy for locally advanced prostate cancer: the roles of radiotherapy, androgen deprivation therapy, and their combination
por: Lee, Sung Uk, et al.
Publicado: (2017)

Long-term outcomes from dose-escalated image-guided intensity-modulated radiotherapy with androgen deprivation: encouraging results for intermediate- and high-risk prostate cancer
por: Wilcox, Shea W, et al.
Publicado: (2014)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Reimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancer
por: Shahinian, Vahakn B, et al.
Publicado: (2015)

Adding radiotherapy to androgen deprivation therapy in men with node-positive prostate cancer after radical prostatectomy: A meta-analysis
por: Guo, Lijuan, et al.
Publicado: (2020)

The Response of Prostate Cancer to Androgen Deprivation and Irradiation Due to Immune Modulation
por: Wu, Chun-Te, et al.
Publicado: (2018)

Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation
por: Hou, Wei-Hsien, et al.
Publicado: (2017)

Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation
por: Geara, Fady B., et al.
Publicado: (2017)

Optimal duration of androgen deprivation therapy following radiation therapy in intermediate- or high-risk non-metastatic prostate cancer: A systematic review and meta-analysis
por: Leal, Frederico, et al.
Publicado: (2015)

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
por: You, Xiangyun, et al.
Publicado: (2023)

Impact of neoadjuvant androgen deprivation therapy on magnetic resonance imaging features in prostate cancer before radiotherapy
por: Björeland, Ulrika, et al.
Publicado: (2021)

Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review
por: Meng, Fanzheng, et al.
Publicado: (2016)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Can we avoid dose escalation for intermediate-risk prostate cancer in the setting of short-course neoadjuvant androgen deprivation?
por: Shakespeare, Thomas P, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_94ivr8tl03vutmgqs6bjuu1ppo